XU Chang, XU Jun,ZHANG Zhi-Yu, SUN Yi, HUANG Dan-Qing, WANG Bian-Rong. Relationship of Homocysteine with Renal Dysfunction in Patients with Leukoaraiosis[J]. Chinese Journal of Stroke, 2019, 14(02): 106-110.
[1] HACHINSKI V C,POTTER P,MERSKEY H.Leukoaraiosis[J]. Arch Neurol,1987,44(1):21-23.[2] HENNINGER N,KHAN M A,ZHANG J,et al.Leukoaraiosis predicts cortical infarct volume afterdistal middle cerebral artery occlusions[J]. Stroke,2014,45(3):689-695.[3] LIU D,DING H,LIU S,et al. Estimated glomerularfiltration rate decline in 567 patients with acutestroke[J]. Scand J Urol Nephrol,2012,46(2):142-147.[4] TOYODA K,NINOMIYA T. Stroke and cerebrovasculardiseases in patients with chronic kidneydisease[J]. Lancet Neuro,2014,13(8):823-833.[5] TURK M,ZUPAN M,ZALETEL M,et al. Carotidarterial hemodynamic in ischenmic levkoaraiosissuggests hypoperfusion mechanism[J]. Eur Neurol,2015,73(56):310-315.[6] THE LADIS STUDY GROUP,POGGESI A,PANTONI L,et al. 2001-2011:a decade of theLADIS(Leukoaraiosis And DISability)Study:whathave we learned about white matter changes andsmall-vessel disease?[J]. Cerebrovasc Dis,2011,32(6):577-588.[7] DEBETTE S,MARKUS H S. The clinicalimportance of white matter hyperintensities on brainmagnetic resonance imaging:systematic review and meta- analysis[J/OL]. BMJ. 2010,341:c3666. https://doi.org/10.1136/bmj.c3666.[8] VERHAAREN F J,VERNOIJ M W,DE BOER R,et al. High blood pressure and cerebral white matterlesion progression in the general population[J].Hypertension,2013,61(6):1354-1359.[9] FAZEKAS F,KLEINERT R,OFFENBACHER H,et al. Pathologic correlates of incidental MRI whitematter signal hyperintensities[J]. Neurology,1993,43(9):1683-1689.[10] CENSORI B,PARTZIGUIAN T. Plasmahomocysteine and severe white matter disease[J].Neurol Sci,2007,28(5):259-263.[11] CHEN Y F,LI PL,ZOU A P. Effect ofhyperhomocysteinemia on plasma or tissueadenosine levels and renal function[J]. Circulation,2002,106(10):1275-1281.[12] ROYBAL C N,YANG S,SUN C W,et al.Homocysteine increases the expression of vascularendothelial growth factor by a mechanism involvingendoplasmic reticulum stress and transcription factorATF4[J]. Biol Chem,2004,279(15):14844-14852.[13] NEMOTO S,TAKEDA K,YU Z X,et al. Rolefor mitochondrial oxidants as regulators of cellularmetabolism[J]. Mol Cell Biol,2000,20(19):7311-7318.[14] MAJORS A K,SENGUPTA S,WILLARD B,et al.Homocysteine binds to [human plasma fibronectinand inhibits its interaction with fibrin[J]. ArteriosclerThromb Vasc Biol,2002,22(8):1354-1359.[15] KIRKLAND G,KHONG T,KATERELOS M,etal. Heparinbinding epidermal growth factor-likegrowth factor is expressed in the adhesive lesions ofexperimental focal glomerular sclerosis[J]. KidneyInt,1999,55(6):2310-2321.[16] PERNA A F,INGROSSO D,SATTA E,et al.Homocysteine metabolism in renal failure[J]. CurrOpin Clin Nutr Metab Care,2004,7(1):53-57.[17] JARDINE M J,KANG A,ZOUNGAS S,et al.The effect of folic acid based homocysteine low oncardiovascular events in people with kidney disease:systematic review and meta-analysis[J/OL]. BMJ,2012,344:e3533. https://doi.org/10.1136/bmj.e3533.[18] HALL S,GODDARD C,OPIO D,et al. Feasibility,acceptability and potential effectiveness of DignityTherapy for older people in care homes:a phase IIrandomized controlled trial of a brief palliative carepsychotherapy[J]. Palliat Med,2011,26(5):703-712.[19] 陆冰,刘洲,王俊贤,等. 不同分级脑白质疏松症患者血清胱抑素C水平的临床意义[J]. 浙江医学,2018,40(10):1091-1093,1098.[20] KHATRI M,WRIGHT C B,NICKOLAS T L,eta1. Chronic kidney disease is associated withwhite matter hyperintensity volume:the NorthernManhattan Study(NOMAS)[J]. Stroke,2007,38(12):3121-3126.[21] CHENG J X,ZHANG H Y,PENG Z K,et al.Divergent topological networks in Alzheimer’sdisease:a diffusion kurtosis imaging analysis[J/OL]. Transl Neurodegener,2018,7:10. https://doi.org/10.1186/s40035-018-0115-y.[22] TOYODA K. Cerebral small vessel disease and chronickidney disease[J]. Stroke,2015,17(1):31-37.[23] FENG C,BAI X,XU Y,et al. Hyperhomocysteinemiaassociates with small vessel disease more closelythan large vessel disease[J]. Int J Med Sci,2013,10(4):408-412.[24] 刘翠梅. 脑白质疏松症危险因素的相关分析研究[D].苏州:苏州大学,2016.[25] SPLAVER A,LAMAS G A,HENNEKENS C H.Homocysteine and cardiovascular disease:biologicalmechanisms,observational epidemiology,and theneed for randomized trials[J]. Am Heart J,2004,148(1):34-40.